INCB040093|INCB 040093;INCB-040093;Dezapelisib

Cas No.:	1262440-25-4
Chemical Name:	6-(3-fluorophenyl)-3-methyl-7-((1S)-1-(9H-purin-6-ylamino)ethyl)-5H-(1,3)thiazolo(3,2-a)pyrimidin-5-one
Synonyms:	INCB 040093;INCB-040093;Dezapelisib
SMILES:	C12SC=C(C)N1C(=O)C(C1=CC=CC(F)=C1)=C([C@H](NC1=C3C(=NC=N1)NC=N3)C)N=2
Formula:	C₂₀H₁₆FN₇Os
M.Wt:	421.454
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM; displays 74 to >900-fold selectivity for the other PI3K family members, and does not inhibit a panel of 57 additional kinases; potently inhibits cellular proliferation CD19+ human or CD21+ canine primary B cells with IC50 of 1-3 nM, reduces anti-FcR-induced basophil activation in the presence of human whole blood (IC50=33 nM); demonstrates promising efficacy in patients with Hodgkin's lymphoma in clinical studies.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC8652	TGR-1202 hydrochloride(Umbralisib)	TGR-1202 hydrochloride is an orally available, next generation PI3Kdelta inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.
DC10150	Tenalisib	Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and PI3Kγ inhibitor with IC50 values of 25 and 33 nM, respectively.
DC11631	INCB040093	A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.